Share Price and Basic Stock Data
Last Updated: November 18, 2025, 4:22 am
| PEG Ratio | 74.93 |
|---|
Analyst Insight & Comprehensive Analysis
Business Overview and Revenue Trends
Caprolactam Chemicals Ltd operates in the chemicals sector, specifically focusing on inorganic products such as caustic soda and soda ash. As of the latest reporting, the company’s stock price stood at ₹43.80, with a market capitalization of ₹20.2 Cr. The revenue trends indicate a fluctuation in sales, with the trailing twelve months (TTM) revenue reported at ₹8.17 Cr. The annual sales figures reveal a significant rise from ₹2.07 Cr in FY 2022 to ₹9.84 Cr in FY 2023, reflecting a robust recovery post-pandemic. However, the company reported a decline in quarterly sales from ₹2.75 Cr in June 2022 to ₹1.49 Cr in December 2023, indicating potential challenges in sustaining growth. A notable aspect is the operating profit margin (OPM), which fluctuated significantly, peaking at 58.18% in June 2022, but reported a decline to 14.29% in March 2025. This volatility in revenue and profitability highlights both growth potential and operational challenges.
Profitability and Efficiency Metrics
Profitability metrics for Caprolactam Chemicals Ltd show a mixed performance, with a reported net profit of -₹0.08 Cr, indicating ongoing challenges in achieving profitability. The operating profit margin (OPM) has varied, with a high of 58.18% in June 2022 and a low of 14.29% in March 2025. The return on equity (ROE) was reported at 13.7%, which is relatively strong compared to industry standards, while the return on capital employed (ROCE) stood at a low 0.48%. The company faced significant fluctuations in its net profit over the past fiscal years, with a peak of ₹2.55 Cr in FY 2023, followed by a decline to -₹0.71 Cr in FY 2025. The cash conversion cycle (CCC) reported at 144.54 days also raises concerns about operational efficiency, indicating a lengthy process in converting inventory into cash, which could strain liquidity.
Balance Sheet Strength and Financial Ratios
The balance sheet of Caprolactam Chemicals Ltd reflects a precarious financial position, characterized by total borrowings of ₹8.72 Cr against reserves of only ₹0.23 Cr. This presents a high debt-to-equity ratio of 1.80, suggesting a reliance on external financing that could heighten financial risk. The current ratio, reported at 0.38, and quick ratio at 0.34, indicate potential liquidity issues, as both ratios fall below the ideal threshold of 1. The interest coverage ratio (ICR) was reported at 2.44, which, while indicating some ability to cover interest expenses, remains on the lower side, suggesting vulnerability during downturns. The company’s book value per share, reported at ₹10.50, has seen fluctuations, signaling instability in net asset value. Overall, the financial ratios portray a company grappling with high leverage and liquidity challenges.
Shareholding Pattern and Investor Confidence
Caprolactam Chemicals Ltd’s shareholding structure shows a significant promoter holding of 54.05%, which reflects a relatively high level of insider confidence in the company’s long-term prospects. The public shareholding stands at 45.94%, with a total of 8,142 shareholders as of March 2025. The stability in promoter holdings over the past quarters, from 52.60% in December 2022 to 54.05% in March 2025, suggests a commitment to the company amidst fluctuating performance metrics. However, the absence of foreign institutional investors (FIIs) and domestic institutional investors (DIIs) could indicate limited external confidence or interest in the stock. This lack of institutional backing may pose risks to liquidity and market perception, especially in times of financial distress. The evolving shareholding pattern underscores the need for the company to enhance its operational performance to attract broader investment interest.
Outlook, Risks, and Final Insight
The outlook for Caprolactam Chemicals Ltd appears mixed, with strengths including a strong recovery in sales growth and a solid promoter holding that reflects confidence in the company’s future. However, risks are evident in the form of a volatile operating profit margin, high debt levels, and liquidity challenges that could hinder operational flexibility. The company’s fluctuating net profit figures highlight ongoing profitability issues, which need to be addressed to ensure sustainable growth. Moving forward, improving operational efficiency and managing debt levels will be crucial for enhancing financial stability. If the company successfully navigates these challenges, it could unlock significant value for shareholders; however, failure to do so may lead to increased financial strain and further declines in market confidence.
Source: Getaka Fundamental Analysis | Generated using proprietary financial data.
Competitors of Caprolactam Chemicals Ltd
| Stock Name ⇩ | Market Cap ⇩ | Current Price ⇩ | High / Low ⇩ | Stock P/E ⇩ | Book Value ⇩ | Dividend Yield ⇩ | ROCE ⇩ | ROE ⇩ | Face Value ⇩ |
|---|---|---|---|---|---|---|---|---|---|
| Caprolactam Chemicals Ltd | 21.9 Cr. | 47.6 | 65.0/37.5 | 2,188 | 11.6 | 0.00 % | 0.48 % | 13.7 % | 10.0 |
| Standard Industries Ltd | 110 Cr. | 17.1 | 31.1/16.0 | 20.4 | 0.00 % | 7.81 % | 10.5 % | 5.00 | |
| Gujarat Alkalies & Chemicals Ltd | 4,051 Cr. | 552 | 823/484 | 27,006 | 759 | 2.86 % | 0.34 % | 1.13 % | 10.0 |
| GHCL Ltd | 5,664 Cr. | 590 | 779/511 | 9.96 | 378 | 2.01 % | 24.2 % | 18.6 % | 10.0 |
| Tata Chemicals Ltd | 21,191 Cr. | 832 | 1,146/756 | 65.0 | 877 | 1.32 % | 3.96 % | 1.20 % | 10.0 |
| Industry Average | 6,349.80 Cr | 424.78 | 5,863.61 | 389.00 | 1.07% | 7.11% | 8.14% | 9.17 |
Quarterly Result
| Metric | Mar 2022 | Jun 2022 | Sep 2022 | Dec 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 0.63 | 2.75 | 2.51 | 2.37 | 2.22 | 2.06 | 1.97 | 1.49 | 1.44 | 1.12 | 1.71 | 2.29 | 1.61 |
| Expenses | 0.55 | 1.15 | 1.24 | 1.28 | 1.51 | 1.30 | 1.52 | 1.20 | 0.77 | 0.87 | 1.14 | 1.82 | 1.38 |
| Operating Profit | 0.08 | 1.60 | 1.27 | 1.09 | 0.71 | 0.76 | 0.45 | 0.29 | 0.67 | 0.25 | 0.57 | 0.47 | 0.23 |
| OPM % | 12.70% | 58.18% | 50.60% | 45.99% | 31.98% | 36.89% | 22.84% | 19.46% | 46.53% | 22.32% | 33.33% | 20.52% | 14.29% |
| Other Income | 0.16 | 0.01 | 0.01 | 0.00 | -0.01 | 0.15 | 0.00 | 0.00 | 0.03 | 0.00 | 0.00 | 0.01 | 0.00 |
| Interest | 0.06 | 0.13 | 0.14 | 0.14 | 0.15 | 0.14 | 0.13 | 0.11 | 0.12 | 0.14 | 0.14 | 0.17 | 0.18 |
| Depreciation | 0.31 | 0.22 | 0.22 | 0.33 | 0.39 | 0.37 | 0.39 | 0.40 | 0.42 | 0.38 | 0.40 | 0.40 | 0.41 |
| Profit before tax | -0.13 | 1.26 | 0.92 | 0.62 | 0.16 | 0.40 | -0.07 | -0.22 | 0.16 | -0.27 | 0.03 | -0.09 | -0.36 |
| Tax % | -107.69% | 24.60% | 25.00% | -17.74% | 0.00% | 25.00% | -28.57% | -31.82% | 31.25% | 0.00% | 0.00% | -66.67% | 25.00% |
| Net Profit | 0.02 | 0.95 | 0.69 | 0.74 | 0.17 | 0.30 | -0.06 | -0.16 | 0.12 | -0.27 | 0.04 | -0.03 | -0.45 |
| EPS in Rs | 0.04 | 2.07 | 1.50 | 1.61 | 0.37 | 0.65 | -0.13 | -0.35 | 0.26 | -0.59 | 0.09 | -0.07 | -0.98 |
Last Updated: May 31, 2025, 6:36 am
Below is a detailed analysis of the quarterly data for Caprolactam Chemicals Ltd based on the most recent figures (Mar 2025) and their trends compared to the previous period:
- For Sales, as of Mar 2025, the value is 1.61 Cr.. The value appears to be declining and may need further review. It has decreased from 2.29 Cr. (Dec 2024) to 1.61 Cr., marking a decrease of 0.68 Cr..
- For Expenses, as of Mar 2025, the value is 1.38 Cr.. The value appears to be improving (decreasing) as expected. It has decreased from 1.82 Cr. (Dec 2024) to 1.38 Cr., marking a decrease of 0.44 Cr..
- For Operating Profit, as of Mar 2025, the value is 0.23 Cr.. The value appears to be declining and may need further review. It has decreased from 0.47 Cr. (Dec 2024) to 0.23 Cr., marking a decrease of 0.24 Cr..
- For OPM %, as of Mar 2025, the value is 14.29%. The value appears to be declining and may need further review. It has decreased from 20.52% (Dec 2024) to 14.29%, marking a decrease of 6.23%.
- For Other Income, as of Mar 2025, the value is 0.00 Cr.. The value appears to be declining and may need further review. It has decreased from 0.01 Cr. (Dec 2024) to 0.00 Cr., marking a decrease of 0.01 Cr..
- For Interest, as of Mar 2025, the value is 0.18 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 0.17 Cr. (Dec 2024) to 0.18 Cr., marking an increase of 0.01 Cr..
- For Depreciation, as of Mar 2025, the value is 0.41 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 0.40 Cr. (Dec 2024) to 0.41 Cr., marking an increase of 0.01 Cr..
- For Profit before tax, as of Mar 2025, the value is -0.36 Cr.. The value appears to be declining and may need further review. It has decreased from -0.09 Cr. (Dec 2024) to -0.36 Cr., marking a decrease of 0.27 Cr..
- For Tax %, as of Mar 2025, the value is 25.00%. The value appears to be increasing, which may not be favorable. It has increased from -66.67% (Dec 2024) to 25.00%, marking an increase of 91.67%.
- For Net Profit, as of Mar 2025, the value is -0.45 Cr.. The value appears to be declining and may need further review. It has decreased from -0.03 Cr. (Dec 2024) to -0.45 Cr., marking a decrease of 0.42 Cr..
- For EPS in Rs, as of Mar 2025, the value is -0.98. The value appears to be declining and may need further review. It has decreased from -0.07 (Dec 2024) to -0.98, marking a decrease of 0.91.
Overall, while many items appear to show a positive trend, any significant downward movement warrant further investigation.
Profit & Loss - Annual Report
Last Updated: October 15, 2025, 3:42 am
| Metric | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 3.92 | 2.85 | 4.88 | 3.23 | 4.07 | 5.19 | 6.51 | 6.31 | 2.07 | 9.84 | 6.96 | 6.74 | 8.17 |
| Expenses | 4.03 | 2.46 | 4.05 | 2.76 | 3.18 | 3.31 | 3.99 | 4.14 | 2.64 | 5.17 | 4.79 | 5.22 | 5.85 |
| Operating Profit | -0.11 | 0.39 | 0.83 | 0.47 | 0.89 | 1.88 | 2.52 | 2.17 | -0.57 | 4.67 | 2.17 | 1.52 | 2.32 |
| OPM % | -2.81% | 13.68% | 17.01% | 14.55% | 21.87% | 36.22% | 38.71% | 34.39% | -27.54% | 47.46% | 31.18% | 22.55% | 28.40% |
| Other Income | 0.01 | -0.15 | 0.40 | 0.01 | 0.07 | 0.07 | 0.06 | 0.09 | 0.41 | 0.02 | 0.18 | 0.01 | 0.01 |
| Interest | 0.00 | 0.06 | 0.11 | 0.12 | 0.19 | 0.34 | 0.30 | 0.30 | 0.28 | 0.57 | 0.50 | 0.63 | 0.67 |
| Depreciation | 0.19 | 0.23 | 0.51 | 0.47 | 0.57 | 0.97 | 1.02 | 1.07 | 1.03 | 1.15 | 1.58 | 1.59 | 1.59 |
| Profit before tax | -0.29 | -0.05 | 0.61 | -0.11 | 0.20 | 0.64 | 1.26 | 0.89 | -1.47 | 2.97 | 0.27 | -0.69 | 0.07 |
| Tax % | -6.90% | 0.00% | 14.75% | 0.00% | 15.00% | 23.44% | 24.60% | 26.97% | -12.93% | 14.14% | 29.63% | 4.35% | |
| Net Profit | -0.27 | -0.06 | 0.52 | -0.12 | 0.17 | 0.50 | 0.95 | 0.65 | -1.28 | 2.55 | 0.20 | -0.71 | -0.08 |
| EPS in Rs | -0.59 | -0.13 | 1.13 | -0.26 | 0.37 | 1.09 | 2.07 | 1.41 | -2.78 | 5.54 | 0.43 | -1.54 | -0.18 |
| Dividend Payout % | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
YoY Net Profit Growth
| Year | 2014-2015 | 2015-2016 | 2016-2017 | 2017-2018 | 2018-2019 | 2019-2020 | 2020-2021 | 2021-2022 | 2022-2023 | 2023-2024 | 2024-2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| YoY Net Profit Growth (%) | 77.78% | 966.67% | -123.08% | 241.67% | 194.12% | 90.00% | -31.58% | -296.92% | 299.22% | -92.16% | -455.00% |
| Change in YoY Net Profit Growth (%) | 0.00% | 888.89% | -1089.74% | 364.74% | -47.55% | -104.12% | -121.58% | -265.34% | 596.14% | -391.38% | -362.84% |
Caprolactam Chemicals Ltd has shown an inconsistent trend in YoY Net Profit Growth (%) in the last 11 years from 2014-2015 to 2024-2025.
Growth
| Compounded Sales Growth | |
|---|---|
| 10 Years: | 9% |
| 5 Years: | 1% |
| 3 Years: | 48% |
| TTM: | 36% |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | 13% |
| TTM: | 78% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | 24% |
| 5 Years: | 23% |
| 3 Years: | -9% |
| 1 Year: | -12% |
| Return on Equity | |
|---|---|
| 10 Years: | 10% |
| 5 Years: | 6% |
| 3 Years: | 14% |
| Last Year: | -14% |
Last Updated: September 5, 2025, 2:51 pm
No data available for the Balance Sheet data table.
Cash Flow - No data available for this post.
Financial Efficiency Indicators
| Month | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debtor Days | 25.14 | 1.28 | 38.89 | 40.68 | 69.05 | 2.81 | 16.82 | 27.19 | 5.29 | 25.22 | 33.56 | 152.72 |
| Inventory Days | 104.29 | 304.17 | 88.78 | 82.64 | 53.85 | 52.14 | 111.68 | |||||
| Days Payable | 43.45 | 861.81 | 799.05 | 344.34 | 173.52 | 111.73 | 119.85 | |||||
| Cash Conversion Cycle | 85.97 | 1.28 | 38.89 | 40.68 | -488.58 | -707.46 | 16.82 | 27.19 | -256.41 | -94.45 | -26.03 | 144.54 |
| Working Capital Days | 20.48 | -189.54 | -71.80 | -169.50 | -232.27 | -274.28 | -158.11 | -106.43 | -689.44 | -94.22 | -267.46 | -314.64 |
| ROCE % | -17.06% | 11.34% | 27.64% | 0.32% | 10.91% | 19.52% | 25.85% | 19.54% | -18.61% | 40.25% | 6.86% | -0.48% |
This stock is not held by any mutual fund.
Key Financial Ratios
| Month | Mar 25 | Mar 24 | Mar 23 | Mar 22 | Mar 21 |
|---|---|---|---|---|---|
| FaceValue | 10.00 | 10.00 | 10.00 | 10.00 | 10.00 |
| Basic EPS (Rs.) | -1.54 | 0.43 | 5.54 | -2.79 | 1.41 |
| Diluted EPS (Rs.) | -1.54 | 0.43 | 5.54 | -2.79 | 1.41 |
| Cash EPS (Rs.) | 1.91 | 3.87 | 8.05 | -0.53 | 3.73 |
| Book Value[Excl.RevalReserv]/Share (Rs.) | 10.50 | 12.06 | 11.61 | 6.08 | 8.87 |
| Book Value[Incl.RevalReserv]/Share (Rs.) | 10.50 | 12.06 | 11.61 | 6.08 | 8.87 |
| Revenue From Operations / Share (Rs.) | 14.65 | 15.12 | 21.39 | 4.50 | 13.72 |
| PBDIT / Share (Rs.) | 3.33 | 5.11 | 10.20 | -0.35 | 4.90 |
| PBIT / Share (Rs.) | -0.11 | 1.67 | 7.69 | -2.60 | 2.58 |
| PBT / Share (Rs.) | -1.49 | 0.59 | 6.46 | -3.20 | 1.94 |
| Net Profit / Share (Rs.) | -1.54 | 0.42 | 5.54 | -2.79 | 1.41 |
| PBDIT Margin (%) | 22.75 | 33.81 | 47.66 | -7.87 | 35.72 |
| PBIT Margin (%) | -0.81 | 11.07 | 35.95 | -57.88 | 18.83 |
| PBT Margin (%) | -10.14 | 3.91 | 30.18 | -71.24 | 14.12 |
| Net Profit Margin (%) | -10.51 | 2.83 | 25.89 | -61.97 | 10.31 |
| Return on Networth / Equity (%) | -14.67 | 3.55 | 47.70 | -45.82 | 15.94 |
| Return on Capital Employeed (%) | -1.12 | 10.62 | 44.09 | -21.52 | 29.13 |
| Return On Assets (%) | -4.96 | 1.69 | 22.12 | -12.40 | 9.30 |
| Long Term Debt / Equity (X) | 0.00 | 0.29 | 0.49 | 0.98 | 0.00 |
| Total Debt / Equity (X) | 1.80 | 1.06 | 1.06 | 1.34 | 0.52 |
| Asset Turnover Ratio (%) | 0.51 | 0.60 | 0.90 | 0.23 | 0.90 |
| Current Ratio (X) | 0.38 | 0.24 | 0.34 | 0.21 | 0.53 |
| Quick Ratio (X) | 0.34 | 0.22 | 0.31 | 0.18 | 0.50 |
| Inventory Turnover Ratio (X) | 28.47 | 6.31 | 5.53 | 4.83 | 0.13 |
| Interest Coverage Ratio (X) | 2.44 | 4.73 | 8.26 | -0.58 | 7.58 |
| Interest Coverage Ratio (Post Tax) (X) | -0.12 | 1.40 | 5.49 | -3.64 | 3.19 |
| Enterprise Value (Cr.) | 28.94 | 29.47 | 29.54 | 25.41 | 16.72 |
| EV / Net Operating Revenue (X) | 4.29 | 4.24 | 3.00 | 12.28 | 2.65 |
| EV / EBITDA (X) | 18.88 | 12.53 | 6.30 | -156.02 | 7.42 |
| MarketCap / Net Operating Revenue (X) | 3.01 | 3.40 | 2.45 | 10.54 | 2.39 |
| Price / BV (X) | 4.21 | 4.27 | 4.51 | 7.79 | 3.70 |
| Price / Net Operating Revenue (X) | 3.01 | 3.41 | 2.45 | 10.54 | 2.39 |
| EarningsYield | -0.03 | 0.01 | 0.10 | -0.05 | 0.04 |
After reviewing the key financial ratios for Caprolactam Chemicals Ltd, here is a detailed analysis based on the latest available data and recent trends:
- For FaceValue, as of Mar 25, the value is 10.00. This value is within the healthy range. There is no change compared to the previous period (Mar 24) which recorded 10.00.
- For Basic EPS (Rs.), as of Mar 25, the value is -1.54. This value is below the healthy minimum of 5. It has decreased from 0.43 (Mar 24) to -1.54, marking a decrease of 1.97.
- For Diluted EPS (Rs.), as of Mar 25, the value is -1.54. This value is below the healthy minimum of 5. It has decreased from 0.43 (Mar 24) to -1.54, marking a decrease of 1.97.
- For Cash EPS (Rs.), as of Mar 25, the value is 1.91. This value is below the healthy minimum of 3. It has decreased from 3.87 (Mar 24) to 1.91, marking a decrease of 1.96.
- For Book Value[Excl.RevalReserv]/Share (Rs.), as of Mar 25, the value is 10.50. It has decreased from 12.06 (Mar 24) to 10.50, marking a decrease of 1.56.
- For Book Value[Incl.RevalReserv]/Share (Rs.), as of Mar 25, the value is 10.50. It has decreased from 12.06 (Mar 24) to 10.50, marking a decrease of 1.56.
- For Revenue From Operations / Share (Rs.), as of Mar 25, the value is 14.65. It has decreased from 15.12 (Mar 24) to 14.65, marking a decrease of 0.47.
- For PBDIT / Share (Rs.), as of Mar 25, the value is 3.33. This value is within the healthy range. It has decreased from 5.11 (Mar 24) to 3.33, marking a decrease of 1.78.
- For PBIT / Share (Rs.), as of Mar 25, the value is -0.11. This value is below the healthy minimum of 0. It has decreased from 1.67 (Mar 24) to -0.11, marking a decrease of 1.78.
- For PBT / Share (Rs.), as of Mar 25, the value is -1.49. This value is below the healthy minimum of 0. It has decreased from 0.59 (Mar 24) to -1.49, marking a decrease of 2.08.
- For Net Profit / Share (Rs.), as of Mar 25, the value is -1.54. This value is below the healthy minimum of 2. It has decreased from 0.42 (Mar 24) to -1.54, marking a decrease of 1.96.
- For PBDIT Margin (%), as of Mar 25, the value is 22.75. This value is within the healthy range. It has decreased from 33.81 (Mar 24) to 22.75, marking a decrease of 11.06.
- For PBIT Margin (%), as of Mar 25, the value is -0.81. This value is below the healthy minimum of 10. It has decreased from 11.07 (Mar 24) to -0.81, marking a decrease of 11.88.
- For PBT Margin (%), as of Mar 25, the value is -10.14. This value is below the healthy minimum of 10. It has decreased from 3.91 (Mar 24) to -10.14, marking a decrease of 14.05.
- For Net Profit Margin (%), as of Mar 25, the value is -10.51. This value is below the healthy minimum of 5. It has decreased from 2.83 (Mar 24) to -10.51, marking a decrease of 13.34.
- For Return on Networth / Equity (%), as of Mar 25, the value is -14.67. This value is below the healthy minimum of 15. It has decreased from 3.55 (Mar 24) to -14.67, marking a decrease of 18.22.
- For Return on Capital Employeed (%), as of Mar 25, the value is -1.12. This value is below the healthy minimum of 10. It has decreased from 10.62 (Mar 24) to -1.12, marking a decrease of 11.74.
- For Return On Assets (%), as of Mar 25, the value is -4.96. This value is below the healthy minimum of 5. It has decreased from 1.69 (Mar 24) to -4.96, marking a decrease of 6.65.
- For Long Term Debt / Equity (X), as of Mar 25, the value is 0.00. This value is below the healthy minimum of 0.2. It has decreased from 0.29 (Mar 24) to 0.00, marking a decrease of 0.29.
- For Total Debt / Equity (X), as of Mar 25, the value is 1.80. This value exceeds the healthy maximum of 1. It has increased from 1.06 (Mar 24) to 1.80, marking an increase of 0.74.
- For Asset Turnover Ratio (%), as of Mar 25, the value is 0.51. It has decreased from 0.60 (Mar 24) to 0.51, marking a decrease of 0.09.
- For Current Ratio (X), as of Mar 25, the value is 0.38. This value is below the healthy minimum of 1.5. It has increased from 0.24 (Mar 24) to 0.38, marking an increase of 0.14.
- For Quick Ratio (X), as of Mar 25, the value is 0.34. This value is below the healthy minimum of 1. It has increased from 0.22 (Mar 24) to 0.34, marking an increase of 0.12.
- For Inventory Turnover Ratio (X), as of Mar 25, the value is 28.47. This value exceeds the healthy maximum of 8. It has increased from 6.31 (Mar 24) to 28.47, marking an increase of 22.16.
- For Interest Coverage Ratio (X), as of Mar 25, the value is 2.44. This value is below the healthy minimum of 3. It has decreased from 4.73 (Mar 24) to 2.44, marking a decrease of 2.29.
- For Interest Coverage Ratio (Post Tax) (X), as of Mar 25, the value is -0.12. This value is below the healthy minimum of 3. It has decreased from 1.40 (Mar 24) to -0.12, marking a decrease of 1.52.
- For Enterprise Value (Cr.), as of Mar 25, the value is 28.94. It has decreased from 29.47 (Mar 24) to 28.94, marking a decrease of 0.53.
- For EV / Net Operating Revenue (X), as of Mar 25, the value is 4.29. This value exceeds the healthy maximum of 3. It has increased from 4.24 (Mar 24) to 4.29, marking an increase of 0.05.
- For EV / EBITDA (X), as of Mar 25, the value is 18.88. This value exceeds the healthy maximum of 15. It has increased from 12.53 (Mar 24) to 18.88, marking an increase of 6.35.
- For MarketCap / Net Operating Revenue (X), as of Mar 25, the value is 3.01. This value exceeds the healthy maximum of 3. It has decreased from 3.40 (Mar 24) to 3.01, marking a decrease of 0.39.
- For Price / BV (X), as of Mar 25, the value is 4.21. This value exceeds the healthy maximum of 3. It has decreased from 4.27 (Mar 24) to 4.21, marking a decrease of 0.06.
- For Price / Net Operating Revenue (X), as of Mar 25, the value is 3.01. This value exceeds the healthy maximum of 3. It has decreased from 3.41 (Mar 24) to 3.01, marking a decrease of 0.40.
- For EarningsYield, as of Mar 25, the value is -0.03. This value is below the healthy minimum of 5. It has decreased from 0.01 (Mar 24) to -0.03, marking a decrease of 0.04.
Overall, while many metrics show healthy performance, any figures highlighted in red or significant downward trends warrant further investigation.
Strength and Weakness
Unable to fetch valid data for stock valuation.Stock Analysis
- Considering all of the following key financial indicators, prospective investors are encouraged to conduct thorough research and seek professional guidance before considering any investment in Caprolactam Chemicals Ltd:
- Net Profit Margin: -10.51%
- Net Profit Margin: This metric indicates the percentage of profit a company makes from its total revenue. A higher net profit margin is generally desirable as it reflects better profitability.
- ROCE: -1.12% (Industry Average ROCE: 7.11%)
- ROCE (Return on Capital Employed): ROCE measures a company's profitability and the efficiency with which its capital is employed. A higher ROCE indicates efficient use of capital.
- ROE%: -14.67% (Industry Average ROE: 8.14%)
- ROE (Return on Equity): ROE measures a company's profitability relative to shareholders' equity. A higher ROE indicates efficient use of shareholders' funds.
- Interest Coverage Ratio (Post Tax): -0.12
- Interest Coverage Ratio: The interest coverage ratio measures a company's ability to cover its interest payments on outstanding debt. A ratio greater than 2 is generally considered healthy as it indicates the company can meet its interest obligations comfortably.
- Quick Ratio: 0.34
- Quick Ratio: The quick ratio assesses a company's ability to cover its short-term liabilities with its most liquid assets. A ratio higher than 1 suggests the company can meet its short-term obligations without relying heavily on inventory.
- Stock P/E: 2 (Industry average Stock P/E: 5)
- Stock P/E (Price-to-Earnings) Ratio: The P/E ratio compares a company's current share price to its earnings per share. A lower P/E ratio relative to industry peers or historical values may indicate that the stock is undervalued.
- Total Debt / Equity: 1.8
- Total Debt / Equity: This ratio measures a company's financial leverage by comparing its total debt to its total equity. A lower ratio indicates lower financial risk and greater financial stability.
Stock Rating: - Net Profit Margin: -10.51%
About the Company - Qualitative Analysis
| INDUSTRY | ADDRESS | CONTACT |
|---|---|---|
| Chemicals - Inorganic - Caustic Soda/Soda Ash | B-31, MIDC, Mahad, Raigad District Maharashtra 402302 | caprolactam@gmail.com http://www.caprolactam.com |
| Management | |
|---|---|
| Name | Position Held |
| Mrs. Zaver Shankarlal Bhanushali | Chairperson & Managing Director |
| Mr. Siddharth Shankarlal Bhanushali | WholeTime Director & CFO |
| Mr. Viren Jaysukhlal Jasani | Ind. Non-Executive Director |
| Mr. Kamlesh Damji Joisher | Ind. Non-Executive Director |
| Mrs. Poonam Bhavin Bhanushali | Ind. Non-Executive Director |